Saraton kasalligi dunyo miqyosida jadal suratlarda rivojlanib borayotgan kasallik hisoblanib,o’lim ko’rsatkichi bo’yicha dunyoda ikkinchi o’rinni egallaydi. Jahon Sogʼliqni saqlash tashkilotining ma’lumotlariga koʼra, 2020-yilda 18.1 mln, 2023-yilda 19.5 mln yangi kasallanish holatlari aniqlangan. 2040-yilga kelib yangi kasallanish koʼrsatkichi 50.7% ga oʼsib 29.4 mln nafarga yetishi bashorat qilinmoqda. Soʼnggi 20 yil ichida dunyo boʼylab saraton kasalligini davolashda qo’llash uchun mo’ljallangan 237 ta yangi faol substansiya sintezlandi. Ularning 115 nafari soʼnggi besh yilllikda sintezlandi. Saraton kasalligini davolashda tirozinkinaza ingibitorlari muhim ahamiyatga ega. Saraton kasalligini davolashda ishlatiladigan dori vositalari zaharli ta’sirga ega moddalar bo’lib, bunday farmakologik ta’sirga ega kam zaharli vositalarni sintezlash va ularning o’tkir zaharliligini baholash va LD50 dozani aniqlash muhim ahamiyatga kasb etadi.
Saraton kasalligi dunyo miqyosida jadal suratlarda rivojlanib borayotgan kasallik hisoblanib,o’lim ko’rsatkichi bo’yicha dunyoda ikkinchi o’rinni egallaydi. Jahon Sogʼliqni saqlash tashkilotining ma’lumotlariga koʼra, 2020-yilda 18.1 mln, 2023-yilda 19.5 mln yangi kasallanish holatlari aniqlangan. 2040-yilga kelib yangi kasallanish koʼrsatkichi 50.7% ga oʼsib 29.4 mln nafarga yetishi bashorat qilinmoqda. Soʼnggi 20 yil ichida dunyo boʼylab saraton kasalligini davolashda qo’llash uchun mo’ljallangan 237 ta yangi faol substansiya sintezlandi. Ularning 115 nafari soʼnggi besh yilllikda sintezlandi. Saraton kasalligini davolashda tirozinkinaza ingibitorlari muhim ahamiyatga ega. Saraton kasalligini davolashda ishlatiladigan dori vositalari zaharli ta’sirga ega moddalar bo’lib, bunday farmakologik ta’sirga ega kam zaharli vositalarni sintezlash va ularning o’tkir zaharliligini baholash va LD50 dozani aniqlash muhim ahamiyatga kasb etadi.
Cancer is a rapidly developing disease worldwide, and it ranks second in the world in terms of mortality rate. According to the World Health Organization, in 2020, 18.1 million, and in 2023, 19.5 million new cases of the disease were detected. By 2040, the number of new cases is predicted to increase by 50.7% to 29.4 million. Over the past 20 years, 237 new active substances designed for use in the treatment of cancer have been synthesized worldwide. 115 of them were synthesized in the last five years. Tyrosine kinase inhibitors are important in the treatment of cancer. Medicines used in the treatment of cancer are substances with toxic effects, and it is important to synthesize less toxic agents with such pharmacological effects andevaluate their acute toxicity and determine the LD50dose
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Saidov R.R. | ! | Toshkent Farmatsevtika Instituti |
| 2 | Elmurodov L.Q. | ! | Toshkent Farmatsevtika Instituti |
| 3 | Gulyamov S.S. | PhD | Toshkent Farmatsevtika Instituti |
| № | Ҳавола номи |
|---|---|
| 1 | 1.Ferlay J. et al. Cancer statistics for the year 2020: An overview // Int J Cancer. 2021. Vol. 149, No 4.1-122.Siegel R.L. et al. Cancer statistics, 2023 // CA Cancer J Clin. 2023. Vol. 73, No 1. 17-483.Karpiński T.M., Adamczak A. Anticancer activity of bacterial proteins and peptides // Pharmaceutics. 2018. Vol. 10, No 2.2-26https://www.iqvia.com/insights/the-iqvia-institute/reports-and publications/reports/global-oncology4.D’Aiello A., Miao E., Cheng H. Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer // Cancers. 2023. Vol.15,No3.4-165.Blaukat A. Tyrosine Kinase Inhibitors // Encyclopedia of Molecular Pharmacology / ed. Offermanns Stefan and Rosenthal W. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. P. 1253–1257.6.Narayan V. et al. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs // JNCCN Journal of the National Comprehensive Cancer Network. 2023. Vol. 21, No 10. 150-1757.Zhong L. et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives // Signal Transduction and Targeted Therapy. 2021.Vol. 6, No 1. 11-488.Shimada A. Hematological malignancies and molecular targeting therapy // European Journal of Pharmacology. 2019. Vol. 862. 124-1389.Hartmann J. et al. Tyrosine Kinase Inhibitors –A Review on Pharmacology, Metabolism and Side Effects // Curr Drug Metab. 2009. Vol. 10, No 5. 252-27610.Morana O., Wood W., Gregory C.D. The Apoptosis Paradox in Cancer // International Journal of Molecular Sciences. 2022. Vol. 23, No 3. 48-6411.Lu L. et al. Tumor necrosis factor-αsensitizes breast cancer cells to natural products with proteasome-inhibitory activity leadingto apoptosis // PLoS One. 2014. Vol. 9, No 11. 23-3812.Han Z. et al. Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review // EJNMMI Research. 2017. Vol. 7.WO 2005/075454A 13.Zhang Z. et al. CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials // Pharmaceutics. 2022. Vol. 14, No 1. 178-19914.Li H. et al. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo // Journal of Experimental and Clinical Cancer Research. 2016. Vol. 35, No 1. 52-6615.Chen X.J. et al. Effect of Etoposide on Elimination of Chronic Myeloid Leukemia Stem Cells by Imatinib in Vivo // Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. Vol. 29, No 2.15-2916.Yevropeyskaya konvensiya po zashite pozvonochnix jivotnix, ispolzuyemix v eksperimentalnix i drugix nauchnix selyax // ETS No 123. 82-981986 –Strasburg (Konvensiya)17.Mironov A.N. Metodicheskiye rekomendatsii po izucheniyu obshetoksicheskogo deystviya lekarstvennix, “Rukovodstvo po provedeniyu doklinicheskix issledovaniy lekarstvennix sredstv” I chast, 2012, Mironov A.N., Bunyatyan N.D. i dr //, 2012 g. S. 15-17.18.Metodi ispitaniye po vozdeystviyu ximicheskoy produksii na organizm cheloveka. Ostraya peroralnaya toksichnost-metod opredeleniye klassa ostroy toksichnosti. (OECD, Test No423: 2001, IDT) Minsk 2013 36-61 19.Karolewicz B. et al. Molecular mobility and stability studies of amorphous imatinib mesylate // Pharmaceutics. 2019. Vol. 11, No 7. 12-2820.Al-Hadiya B.M.H., Bakheit A.H.H., Abd-Elgalil A.A. Chapter Six –Imatinib Mesylate // Profiles of Drug Substances, Excipients and Related Methodology. 2014. Vol. 39. 124-135 |